BIOLASE, Inc., along with its various divisions, operates as a global enterprise specializing in the creation, production, distribution, and sale of advanced ...
Biolase, Inc. is a leading innovator in the dental laser industry, headquartered in Lake Forest, California. The company focuses on the development and manufacturing of advanced laser-based dental systems that allow dentists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. Their flagship ...Biolase, Inc. is a leading innovator in the dental laser industry, headquartered in Lake Forest, California. The company focuses on the development and manufacturing of advanced laser-based dental systems that allow dentists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. Their flagship products, such as the Waterlase and Epic laser systems, represent a shift toward less painful, more efficient dental care by utilizing proprietary hydrokinetic and diode technology.
From a business perspective, Biolase operates in the highly specialized medical technology sector. Their revenue is derived primarily from the sale of laser systems, consumable dental instruments, and recurring service/maintenance contracts. The company faces stiff competition from both traditional dental equipment manufacturers and emerging digital dentistry solutions. A critical aspect of their business model is the 'razor-and-blade' strategy, where the initial capital expenditure of the laser unit is supported by the ongoing sale of proprietary tips and service agreements.
Financial performance for Biolase has historically been volatile, characteristic of small-cap medical device firms focused on R&D-heavy product cycles. Cost management, particularly in manufacturing (BOM) and research and development, remains a key priority for management. Key leadership, including CEO John Beaver, is tasked with expanding market penetration in both the domestic and international dental markets. Looking toward the future, the company aims to establish its laser systems as the standard of care for periodontal treatment and endodontics. Despite challenges, their commitment to innovation continues to drive efforts to lower the barrier to entry for dentists to adopt laser technology, ultimately aiming to improve patient outcomes while enhancing the efficiency of modern dental practices.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$49.2M
+1.4%
-6.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-20.6M
+27.9%
+49.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+34.0%
+3.6%
+1.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-36.5%
+30.2%
+77.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-42.0%
+29.0%
+45.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-15.4M
+49.5%
-492.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-31.3%
+50.2%
-531.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-7251.0%
-2359.7%
-5.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.26x
-22.2%
-11.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would now like to turn the conference over to Mr. Michael Polyviou. Please go ahead, sir.
Michael Polyviou: Thank you, Chuck. Good afternoon, everyone, and thank you for joining us today to discuss BIOLASE's financial results for its first quarter ended March 31, 2024. On the call today from BIOLASE are John Beaver, President and Chief Executive Officer; and Jennifer Bright, Chief Financial Officer. John will review the company's operating performance for the first quarter and then turn the call over to Jennifer to review the financials in more detail before opening the call for questions. Before we begin, I'd like to remind everyone that a number of forward-looking statements, which are any statements that are not historical facts will be made during this presentation and subsequent Q&A session, including forward-looking statements regarding the company's strategic initiatives and anticipated financial performance. These forward-looking statements are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 and based on BIOLASE's current expectations and assumptions and are subject to a variety of risks and uncertainties that could cause the company's actual results to differ materially from the statements made. Such forward-looking statements only represent the company's view as of today, May 13, 2024. These risks are discussed in the company's filings with the Securities and Exchange Commission. A replay of this conference call will be available on BIOLASE's website shortly after the completion of today's call. When listening to this call, please refer to the news release issued earlier today announcing the company's 2024 first quarter financial results. If you do not have a copy of the news release, it is available in the Investors section of BIOLASE website at www.biolase.com. BIOLASE's financial results can also be found in the company's report on Form 10-Q, which will be filed with the SEC just a few minutes ago. The tables we provided in today's news release offer additional financial information, so we encourage you to review them. The tables include the reconciliation of unaudited GAAP net loss and net loss per share to non-GAAP adjusted EBITDA loss and adjusted EBITDA loss per share as well as more information regarding the company's non-GAAP disclosures. With that, I'll turn the call over to John Beaver, BIOLASE's President, Chief Executive Officer. John, please go ahead.
John Beaver: Thanks, Michael, and thank you, everyone, for joining us this afternoon. We appreciate your continued interest in BIOLASE. I want to start by restating our primary objective, which is to ensure our industry-leading dental lasers …
